̽»¨ºÏ¼¯ Makes Two Key European Appointments In Oral Dose Manufacturing
Dr. Irmgard Neuper is the new General Manager at ̽»¨ºÏ¼¯â€™s Schorndorf facility, which provides large scale, complex oral solid manufacturing with integrated analytical, development, and packaging services.
Dr. Neuper joins ̽»¨ºÏ¼¯ from Sandoz, with 17 years of operating and leadership experience in Technical Operations functions in Austria, USA, Germany and Brazil, where she gained significant expertise in manufacturing, from early pharmaceutical intermediates to finished dosage forms. Her most recent role at Sandoz was as Site Head at the company’s Gerlingen, Germany, facility.
Prior to this, she served in a number of roles at Sandoz, including Global Quality Project Manager; Site Head for Solid Oral Dosage forms and Liquids in Brazil; Head of Production for Frankfurt Industrial products; and Project Manager for R&D at the Geneva, USA, site.
Dr. Neuper has a PhD in Agricultural Sciences and a Diploma in Engineering for Food and Biotechnology, both from University for Agricultural Sciences, Vienna.
In a second announcement, Luc Burgard will become the new General Manager of ̽»¨ºÏ¼¯â€™s 360,000 sq.ft. Eberbach softgel manufacturing facility.
Mr. Burgard joined ̽»¨ºÏ¼¯ in October 2011 as European Operational Excellence Leader, based in Beinheim, France, before being appointed as Operations Director at the Eberbach site in April 2013. Prior to joining ̽»¨ºÏ¼¯, he was employed by Faurecia, a global automotive technology supplier for 9 years, working in progressively senior operational roles including the Global Leader in Engineering Methodologies.
Mr. Burgard holds a Bachelor’s Degree in electronics and quality from Cergy-Pontoise University, as well as an Advanced Master’s Degree in innovative design and mathematics from the Institut National des Sciences Appliquées of Strasbourg.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About ̽»¨ºÏ¼¯
̽»¨ºÏ¼¯ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, ̽»¨ºÏ¼¯ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. ̽»¨ºÏ¼¯ employs approximately 8,600 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. ̽»¨ºÏ¼¯ is headquartered in Somerset, N.J. For more information, visit www.catalent.com.